Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Betere uitkomsten COVID-19 dankzij therapeutische antistolling
sep 2021 | Benigne hematologie, Pneumonie, Virale infecties